In conclusion, our results suggest that MYCT1 inhibits the expression of RUNX1 by inhibiting the binding ability between MAX and the RUNX1 promoter region, thereby affecting the proliferation and cell cycle process of DLBCL cells. The gene discussed is MAX; the disease is diffuse large B-cell lymphoma.